Utidelone
- Generic Name
- Utidelone
- Drug Type
- Small Molecule
- Background
Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering. It is under investigation in clinical trials for various cancers.
- Indication
联合卡培他滨，用于既往接受过至少一种化疗方案的复发或转移性乳腺癌患者。
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
- Conditions
- HER-2 Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 71
- Registration Number
- NCT05398861
Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05357417
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05299255
- Locations
- 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast NeoplasmsLocally Advanced or Metastatic Breast Cancer
- Interventions
- Drug: Taxane plus Metronomic CapecitabineDrug: Taxane plus Intermittent Capecitabine
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 512
- Registration Number
- NCT05172518
- Locations
- 🇨🇳
Shusen Wang, Guangzhou, Guangdong, China
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
- Conditions
- Advanced and Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05052437
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04911907
- Locations
- 🇨🇳
Luhe Hospital, Capital Medical University, Beijing, China
🇨🇳Shanghai East Hospital of Tongji University, Shanghai, China
🇨🇳Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03906565
- Locations
- 🇨🇳
Tianjin People's Hospital, Tianjin, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT03693547
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Peking Union Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.